




Instance: composition-en-28b6beabb1138dcf80cd8cb464115640
InstanceOf: CompositionUvEpi
Title: "Composition for veoza Package Leaflet"
Description:  "Composition for veoza Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd33add2b5d5f8d930b0c810b6da2f4fa)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - veoza"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Veoza is and what it is used for </li>
<li>What you need to know before you take Veoza </li>
<li>How to take Veoza </li>
<li>Possible side effects </li>
<li>How to store Veoza </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What veoza is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What veoza is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Veoza contains the active substance fezolinetant. Veoza is a non-hormonal medicine used in 
menopausal women to reduce moderate-to-severe vasomotor symptoms (VMS) associated with 
menopause. VMS are also known as hot flashes or night sweats. </p>
<p>Before menopause, there is a balance between oestrogens, a female sex hormone, and a protein made 
by the brain known as neurokinin B (NKB) that regulates your brain s temperature control centre. As 
your body goes through menopause, oestrogen levels decline and this balance is disrupted, which can 
lead to VMS. By blocking NKB binding in your temperature control centre, Veoza reduces the number 
and intensity of hot flashes and night sweats. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take veoza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take veoza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Veoza 
- if you are allergic to fezolinetant or any of the other ingredients of this medicine (listed in 
section 6). 
- with medicines known as moderate or strong CYP1A2 inhibitors (e.g., ethinyl oestradiol 
containing contraceptives, mexiletine, enoxacin, fluvoxamine). These medicines can reduce the 
breakdown of Veoza in the body, leading to more side effects. See  Other medicines and Veoza<br />
below. 
- if you are pregnant or think you may be pregnant. 
Warnings and precautions 
Talk to your doctor or pharmacist before taking Veoza 
- your doctor may ask for your full medical history, including family history. 
- if you have ongoing liver disease or liver problems. Your doctor may want to monitor your liver 
enzymes periodically. 
- if you have kidney problems. Your doctor may not prescribe this medicine to you. 
- if you currently have or previously had breast cancer or another oestrogen-related cancer. 
During treatment, your doctor may not prescribe this medicine to you. 
- if you are taking hormone replacement therapy with oestrogens (medicines used to treat 
oestrogen deficiency symptoms). Your doctor may not prescribe this medicine to you. 
- if you have a history of seizures. Your doctor may not prescribe this medicine to you. 
Children and adolescents 
Do not give this medicine to children and adolescents under 18 years of age, because this medicine is 
only for menopausal women. 
Other medicines and Veoza 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, including medicines without a prescription. </p>
<p>Certain medicines may increase the risk of side effects of Veoza by increasing the amount of Veoza in 
the blood. These medicines must not be taken while you are taking Veoza, and include:</p>
<ul>
<li>Fluvoxamine (a medicine used to treat depression and anxiety) </li>
<li>Enoxacin (a medicine used to treat infections) </li>
<li>Mexiletine (a medicine used to treat symptoms of muscle stiffness) </li>
<li>Ethinyl oestradiol containing contraceptives (medicines used to prevent pregnancy) 
Pregnancy and breast-feeding 
Do not take this medicine if you are pregnant or breast-feeding, or if you think you might be pregnant. 
This medicine is for use only by menopausal women. If you become pregnant while taking this 
medicine, stop taking it immediately and talk to your doctor. Women of childbearing potential should 
use effective non-hormonal contraception. 
Driving and using machines 
Veoza has no effect on the ability to drive or use machines. </li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take veoza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take veoza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is one 45 mg tablet taken by mouth once daily. 
Instructions for proper use 
- Take this medicine at about the same time each day. 
- Swallow the tablet whole with liquids. Do not break, crush, or chew the tablet. 
- Take with or without food. 
If you take more Veoza than you should 
If you have taken more tablets than you have been told to take, or if someone else accidentally takes 
your tablets, contact your doctor or pharmacist straight away. </p>
<p>Symptoms of overdose may include headache, feeling sick (nausea), or a tingling or prickling 
sensation (paraesthesia). 
If you forget to take Veoza 
If you forget to take your medicine, take the missed dose as soon as you remember on the same day, 
and at least 12 hours before the next scheduled dose. If there is less than 12 hours before the next 
scheduled dose, do not take the missed dose. Return to your regular schedule the following day. Do 
not take a double dose to make up for a forgotten individual dose. </p>
<p>If you miss several doses, tell your doctor and follow the advice given to you. 
If you stop taking Veoza 
Do not stop taking this medicine unless your doctor tells you to do so. If you decide to stop taking this 
medicine before finishing the prescribed course of treatment, you should talk to your doctor first. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Common (may affect up to 1 in 10 people) 
- diarrhoea 
- difficulty sleeping (insomnia) 
- increase in levels of certain liver enzymes (ALT or AST), as shown in blood tests 
- stomach (abdominal) pain 
Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store veoza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store veoza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Veoza contains 
- The active substance is fezolinetant. Each film-coated tablet contains 45 mg of fezolinetant. 
- The other ingredients are: 
Tablet core: mannitol (E421), hydroxypropyl cellulose (E463), low-substituted hydroxypropyl 
cellulose (E463a), microcrystalline cellulose (E460), magnesium stearate (E470b). 
Film-coating: hypromellose (E464), talc (E553b), macrogol (E1521), titanium dioxide (E171), 
iron oxide red (E172). 
What Veoza looks like and contents of the pack 
Veoza 45 mg tablets are round, light red, film-coated tablets (tablets) debossed with the company logo<br />
and  645  on the same side. </p>
<p>Veoza is available in PA/Aluminium/PVC/Aluminium unit dose blisters in cartons. </p>
<p>Pack sizes: 10   1, 28   1, 30   1, and 100   1 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. 
Marketing Authorisation Holder and Manufacturer 
Astellas Pharma Europe B.V. 
Sylviusweg 2333 BE Leiden 
The Netherlands 
Tel: +31 (0)71 5455For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Astellas Pharma B.V. Branch 
T l/Tel: +32 (0)2 5580Lietuva 
Astellas Pharma d.o.o. 
Tel.: +370 37 408   </p>
<p>Te .: +359 2 862 53 Luxembourg/Luxemburg 
Astellas Pharma B.V. Branch 
Belgique/Belgien 
T l/Tel: +32 (0)2 5580 esk  republika 
Astellas Pharma s.r.o. 
Tel: +420 221 401 Magyarorsz g 
Astellas Pharma Kft. 
Tel.: +36 1 577 8Danmark 
Astellas Pharma a/s 
Tlf: +45 43 430Malta 
Astellas Pharmaceuticals AEBE 
Tel: +30 210 8189Deutschland 
Astellas Pharma GmbH 
Tel.: +49 (0)89 454Nederland 
Astellas Pharma B.V. 
Tel: +31 (0)71 5455Eesti 
Astellas Pharma d.o.o. 
Tel: +372 6 056 Norge 
Astellas Pharma 
Tlf: +47 66 76 46 <br />
Astellas Pharmaceuticals AEBE 
 : +30 210 8189 sterreich 
Astellas Pharma Ges.m.b.H. 
Tel.: +43 (0)1 8772Espa a 
Astellas Pharma S.A. 
Tel: +34 91 4952Polska 
Astellas Pharma Sp.z.o.o. 
Tel.: +48 225451 France 
Astellas Pharma S.A.S. 
T l: +33 (0)1 55917Portugal 
Astellas Farma, Lda. 
Tel: +351 21 4401Hrvatska 
Astellas d.o.o. 
Tel: +385 1670 0Rom nia 
S.C.Astellas Pharma SRL 
Tel: +40 (0)21 361 04 Ireland 
Astellas Pharma Co. Ltd. 
Tel: +353 (0)1 4671Slovenija 
Astellas Pharma d.o.o. 
Tel: +386 14011 sland 
Vistor hf 
S mi: +354 535 7Slovensk  republika 
Astellas Pharma s.r.o. 
Tel: +421 2 4444 2Italia 
Astellas Pharma S.p.A. 
Tel: +39 (0)2 921Suomi/Finland 
Astellas Pharma 
Puh/Tel: +358 (0)9 85606  </p>
<p>Astellas Pharmaceuticals AEBE 
 : +30 210 8189Sverige 
Astellas Pharma AB 
Tel: +46 (0)40-650 15 Latvija 
Astellas Pharma d.o.o. 
Tel: +371 67 619United Kingdom (Northern Ireland) 
Astellas Pharma Co., Limited 
Free call from Northern Ireland: 0800 783 5International number: +353 (0)1 4671This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. </p>         </div>"""      



Instance: composition-da-28b6beabb1138dcf80cd8cb464115640
InstanceOf: CompositionUvEpi
Title: "Composition for veoza Package Leaflet"
Description:  "Composition for veoza Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd33add2b5d5f8d930b0c810b6da2f4fa)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - veoza"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Veoza 
3. Sådan skal du tage Veoza 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What veoza is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What veoza is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Veoza indeholder det aktive stof fezolinetant. Veoza er et ikke-hormonelt lægemiddel, der anvendes 
hos kvinder i overgangsalderen til at reducere moderate til svære vasomotoriske symptomer (VMS), 
som er forbundet med overgangsalderen. VMS er også kendt som hedeture eller nattesved. </p>
<p>Inden overgangsalderen er der balance mellem østrogener, et kvindeligt kønshormon, og et protein 
fremstillet af hjernen, der kaldes neurokinin B (NKB), som styrer hjernens temperaturregulerende 
center. Når din krop går gennem overgangsalderen, sker der en nedgang i østrogenniveauerne, og 
denne balance forstyrres. Dette kan medføre VMS. Ved at blokere NKB-binding i dit 
temperaturregulerende center reducerer Veoza antallet og intensiteten af hedeture og nattesved. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take veoza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take veoza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Veoza 
- hvis du er allergisk over for fezolinetant eller et af de øvrige indholdsstoffer i Veoza (angivet i 
punkt 6). 
- sammen med lægemidler, som er kendte som moderate eller stærke CYP1A2-hæmmere (f.eks. 
ethinylestradiolholdige præventionsmidler, mexiletin, enoxacin, fluvoxamin). Disse lægemidler 
kan reducere nedbrydelsen af Veoza i kroppen, hvilket resulterer i flere bivirkninger. Se "Brug 
af andre lægemidler sammen med Veoza" nedenfor. 
- hvis du er gravid eller har mistanke om, at du er gravid. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Veoza 
- din læge kan spørge til hele din sygehistorie, herunder familiens historie. 
- hvis du har aktiv leversygdom eller leverproblemer. Din læge vil muligvis overvåge dine 
leverenzymer med jævne mellemrum. 
- hvis du har nyreproblemer. Din læge vil måske ikke ordinere dette lægemiddel til dig. 
- hvis du har eller tidligere har haft brystkræft eller anden østrogenrelateret kræftsygdom. Under 
behandlingen vil din læge muligvis ikke ordinere dette lægemiddel til dig. 
- hvis du tager hormonerstatningsbehandling med østrogener (lægemidler, der anvendes til at 
behandle symptomer på østrogenmangel). Din læge vil måske ikke ordinere dette lægemiddel til 
dig. 
- hvis du tidligere har haft krampeanfald. Din læge vil måske ikke ordinere dette lægemiddel til dig.<br />
Børn og unge 
Børn og unge under 18 år må ikke få dette lægemiddel, da dette lægemiddel kun er til kvinder i 
overgangsalderen. 
Brug af andre lægemidler sammen med Veoza 
Fortæl lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler, herunder lægemidler, som fås uden recept. </p>
<p>Visse lægemidler kan øge risikoen for bivirkninger af Veoza ved at øge mængden af Veoza i blodet. 
Disse lægemidler må ikke tages, mens du tager Veoza, og omfatter:</p>
<ul>
<li>Fluvoxamin (et lægemiddel, der anvendes til behandling af depression og angst) </li>
<li>Enoxacin (et lægemiddel, der anvendes til behandling af infektioner) </li>
<li>Mexiletin (et lægemiddel, der anvendes til behandling af muskelstivhed) </li>
<li>Ethinylestradiolholdige præventionsmidler (lægemidler, der anvendes til at forhindre graviditet) 
Graviditet og amning 
Hvis du er gravid eller ammer eller har mistanke om, at du er gravid, må du ikke tage dette 
lægemiddel. Dette lægemiddel må kun anvendes af kvinder i overgangsalderen. Hvis du bliver gravid, 
mens du tager dette lægemiddel, skal du øjeblikkeligt stoppe med at tage det, og tale med lægen. 
Kvinder i den fødedygtige alder skal anvende sikker ikke-hormonel prævention. 
Trafik- og arbejdssikkerhed 
Veoza påvirker ikke evnen til at føre motorkøretøj eller betjene maskiner. </li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take veoza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take veoza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er én 45 mg-tablet, der tages gennem munden én gang dagligt. 
Anvisninger til korrekt brug 
- Tag dette lægemiddel omtrent på samme tidspunkt hver dag. 
- Synk tabletten hel sammen med væske. Tabletten må ikke knækkes, knuses eller tygges. 
- Kan tages med eller uden mad. 
Hvis du har taget for meget Veoza 
Hvis du har taget flere tabletter, end du har fået at vide, du skulle tage, eller hvis en anden person ved 
et uheld har indtaget dine tabletter, skal du straks kontakte lægen eller apotekspersonalet. </p>
<p>Symptomer på overdosering kan omfatte hovedpine, kvalme eller en prikkende eller stikkende 
fornemmelse (paræstesi). </p>
<p>Hvis du har glemt at tage Veoza 
Hvis du glemmer at tage lægemidlet, skal du tage den glemte dosis, så snart du husker det samme dag, 
men der skal være mindst 12 timer til den næste planlagte dosis. Hvis der er mindre end 12 timer til 
den næste planlagte dosis, må du ikke tage den glemte dosis. Vend tilbage til din almindelige plan den 
næste dag. Du må ikke tage en dobbeltdosis som erstatning for den glemte individuelle dosis. </p>
<p>Hvis du har glemt flere doser, skal du fortælle det til din læge og følge de råd, du får. 
Hvis du holder op med at tage Veoza 
Du må ikke stoppe med at tage dette lægemiddel, medmindre din læge beder dig om det. Hvis du 
beslutter dig for at stoppe med at tage dette lægemiddel, inden du har afsluttet det ordinerede 
behandlingsforløb, skal du først tale med lægen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Almindelig (kan forekomme hos op til 1 ud af 10 personer) 
- diarré 
- søvnløshed (insomni) 
- stigning i visse leverenzymer (ALAT eller ASAT), som påvises ved blodprøver 
- mavesmerter. 
Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store veoza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store veoza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. 
Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og blisterpakningen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Veoza indeholder 
- Aktivt stof: fezolinetant. Hver filmovertrukket tablet indeholder 45 mg fezolinetant. 
- Øvrige indholdsstoffer: 
Tabletkerne: mannitol (E421), hydroxypropylcellulose (E463), lavsubstitueret 
hydroxypropylcellulose (E463a), mikrokrystallinsk cellulose (E460), magnesiumstearat 
(E470b). 
Filmovertræk: hypromellose (E464), talcum (E553b), macrogol (E1521), titandioxid (E171), rød 
jernoxid (E172). </p>
<p>Udseende og pakningsstørrelser 
Veoza 45 mg tabletter er runde, lyserøde, filmovertrukne tabletter (tabletter) præget med firmalogo og 
"645" på samme side. </p>
<p>Veoza er tilgængelig i PA/aluminium/PVC/aluminium-enkeltdosisblistere i kartoner. </p>
<p>Pakningsstørrelser: 10 × 1, 28 × 1, 30 × 1 og 100 × 1 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. 
Indehaver af markedsføringstilladelsen 
Astellas Pharma Europe B.V. 
Sylviusweg 2333 BE Leiden 
Holland </p>
<p>Fremstiller 
Delpharm Meppel B.V. 
Hogemaat 2 
7942 JG Meppel 
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Astellas Pharma B.V. Branch 
Tél/Tel: +32 (0)2 5580 
Lietuva 
Astellas Pharma d.o.o. 
Tel.: +370 37 408<br />
България 
Астелас Фарма ЕООД 
Teл.: +359 2 862 53<br />
Luxembourg/Luxemburg 
Astellas Pharma B.V. Branch 
Belgique/Belgien 
Tél/Tel: +32 (0)2 5580 
Česká republika 
Astellas Pharma s.r.o. 
Tel: +420 221 401<br />
Magyarország 
Astellas Pharma Kft. 
Tel.: +36 1 577 8 
Danmark 
Astellas Pharma a/s 
Tlf: +45 43 430 
Malta 
Astellas Pharmaceuticals AEBE 
Tel: +30 210 8189 
Deutschland 
Astellas Pharma GmbH 
Tel.: +49 (0)89 454 
Nederland 
Astellas Pharma B.V. 
Tel: +31 (0)71 5455 
Eesti 
Astellas Pharma d.o.o. 
Tel: +372 6 056<br />
Norge 
Astellas Pharma 
Tlf: +47 66 76 46<br />
Ελλάδα 
Astellas Pharmaceuticals AEBE 
Τηλ: +30 210 8189 
Österreich 
Astellas Pharma Ges.m.b.H. 
Tel.: +43 (0)1 8772 </p>
<p>España 
Astellas Pharma S.A. 
Tel: +34 91 4952 
Polska 
Astellas Pharma Sp.z.o.o. 
Tel.: +48 225451 France 
Astellas Pharma S.A.S. 
Tél: +33 (0)1 55917 
Portugal 
Astellas Farma, Lda. 
Tel: +351 21 4401 
Hrvatska 
Astellas d.o.o. 
Tel: +385 1670 0 
România 
S.C. Astellas Pharma SRL 
Tel: +40 (0)21 361 04<br />
Ireland 
Astellas Pharma Co. Ltd. 
Tel: +353 (0)1 4671 
Slovenija 
Astellas Pharma d.o.o. 
Tel: +386 14011 
Ísland 
Vistor hf 
Sími: +354 535 7 
Slovenská republika 
Astellas Pharma s.r.o. 
Tel: +421 2 4444 2 
Italia 
Astellas Pharma S.p.A. 
Tel: +39 (0)2 921 
Suomi/Finland 
Astellas Pharma 
Puh/Tel: +358 (0)9 85606 
Κύπρος 
Ελλάδα 
Astellas Pharmaceuticals AEBE 
Τηλ: +30 210 8189 
Sverige 
Astellas Pharma AB 
Tel: +46 (0)40-650 15<br />
Latvija 
Astellas Pharma d.o.o. 
Tel: +371 67 619 
United Kingdom (Northern Ireland) 
Astellas Pharma Co., Limited 
Tel: +353 (0)1 4671Free call from Northern Ireland: 0800 783 5 </p>
<p>Denne indlægsseddel blev senest ændret    </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-28b6beabb1138dcf80cd8cb464115640
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for veoza Package Leaflet for language en"
Description: "ePI document Bundle for veoza Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-28b6beabb1138dcf80cd8cb464115640"
* entry[0].resource = composition-en-28b6beabb1138dcf80cd8cb464115640

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp28b6beabb1138dcf80cd8cb464115640"
* entry[=].resource = mp28b6beabb1138dcf80cd8cb464115640
                            
                    
Instance: bundlepackageleaflet-da-28b6beabb1138dcf80cd8cb464115640
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for veoza Package Leaflet for language da"
Description: "ePI document Bundle for veoza Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-28b6beabb1138dcf80cd8cb464115640"
* entry[0].resource = composition-da-28b6beabb1138dcf80cd8cb464115640

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp28b6beabb1138dcf80cd8cb464115640"
* entry[=].resource = mp28b6beabb1138dcf80cd8cb464115640
                            
                    



Instance: mp28b6beabb1138dcf80cd8cb464115640
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product veoza"
Description: "veoza"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1771/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "veoza"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 28b6beabb1138dcf80cd8cb464115640ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "veoza"

* status = #current
* mode = #working

* title = "List of all ePIs associated with veoza"

* subject = Reference(mpd33add2b5d5f8d930b0c810b6da2f4fa)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#veoza "veoza"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-28b6beabb1138dcf80cd8cb464115640) // veoza en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-28b6beabb1138dcf80cd8cb464115640) // veoza da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-28b6beabb1138dcf80cd8cb464115640
InstanceOf: List

* insert 28b6beabb1138dcf80cd8cb464115640ListRuleset
    